Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

190 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A total of 145 Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) were retrospectively enrolled at Kaohsiung Chang Gung Memorial Hospital between 2006 and 2019. Clinical records from 7 days before LT (pre-LT) to 1 year after LT (post-LT) were analysed. In a prospective study from March 2022 to June 2023, 20 lymphopenia and 25 non-lymphopenia HCC recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Uses of Immunosuppression Therapy in Patients With Liver Transplantation

NCT01834690

Evidence of Liver Transplantation

COMPLETED

Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation

NCT01444079

Liver Transplant Rejection

COMPLETED

Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study

NCT06045949

Liver and Biliary Tract Disorders in Duration of Pregnancy Other End-stage Liver Diseases in Children

COMPLETED

Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.

NCT06636409

Liver Transplant

ACTIVE_NOT_RECRUITING

Longitudinal Follow-up and Health-Related Outcomes in Liver Transplant Recipients and Living Donors

NCT07301853

Living Donor Liver Transplantation Recipients Deceased Donor Liver Transplantation Recipients Living Liver Donor

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 145 Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) were retrospectively enrolled at Kaohsiung Chang Gung Memorial Hospital between 2006 and 2019. Clinical records from 7 days before LT (pre-LT) to 1 year after LT (post-LT) were analysed including overall survival, recurrence-free survival, association between clinical parameter with mortality, patient characteristics by pre-lymphopenia and post-lymphopenia levels and lymphocyte status of HCC patients with usage of different immunosuppressants. In prospective study from March 2022 to June 2023, 20 lymphopenia and 25 non-lymphopenia HCC recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry to identify the major immune cell subsets and the characteristics of patients in the prospective cohort between pre-LT lymphopenia and non-lymphopenia groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* liver transplant patient

Exclusion Criteria

* End-stage liver disease scoring system score (MELD score) \> 25
* Have received care in the intensive care unit (ICU) before transplantation
* Poor cardiovascular function.
* Patients suffering active infection.
* Other complications affecting living donor liver transplantation

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No